Rapid-onset leucoderma associated with graft-versus-host disease [2]

Bone Marrow Transplantation

Volumn 30, Issue 10, 2002, Pages 705-706

  Jacobsohn, D A ^a   Ruble, K ^a   Moresi, J M ^a   Vogelsang, G B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN; CYTARABINE; IMMUNOSUPPRESSIVE AGENT; STEROID; TACROLIMUS;

ADOLESCENT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKODERMA; MALE; PRIORITY JOURNAL; PUVA; SKIN BIOPSY; VITILIGO; WHOLE BODY RADIATION; BONE MARROW TRANSPLANTATION; HYPOPIGMENTATION; IMMUNOLOGY; METHODOLOGY; PATHOLOGY; TIME;

ADOLESCENT; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; HYPOPIGMENTATION; HYPOTHYROIDISM; MALE; TIME FACTORS; TRANSPLANTATION CONDITIONING;

EID: 0036861876     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703724     Document Type: Letter

References (8)

1. Jacobsohn DA, Montross S, Anders V et al. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transplant 2001; 28: 1047-1051.
2. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
3. Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545-570.
4. Saurat JH, Gluckman E. Lichen-planus-like eruption following bone marrow transplantation: a manifestation of the graft-versus-host disease. Clin Exp Dermatol 1977; 2: 335-344.
5. Nagler A, Goldenhersh MA, Levi-Schaffer F et al. Total leucoderma: a rare manifestation of cutaneous chronic graft-versus-host disease. Br J Dermatol 1996; 134: 780-783.
6. Aubin F, Cahn JY, Ferrand C et al. Extensive vitiligo after ganciclovir treatment of GvHD in a patient who had received donor T cells expressing herpes simplex virus thymidine kinase. Lancet 2000; 355: 626-627.
7. Yee C, Thompson JA, Roche P et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000; 192: 1637-1643.
8. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167-181.